This makes ritlecitinib the first medicine authorized by the EC to treat individuals with severe alopecia areata as young as 12 years of age.
that evaluated ritlecitinib in patients aged 12 years and older with alopecia areata with 50% or more scalp hair loss, including patients with alopecia totalis and alopecia universalis . Results from this study showed that 13.4% of adults and adolescents achieved 90% or more scalp hair coverage after 24 weeks of treatment with ritlecitinib 50 mg, compared with 1.5% of those on placebo.
The study also measured Patient Global Impression of Change . At week 24, 49.2% of participants treated with ritlecitinib reported a PGI-C response of"moderate" to"great" improvement in their alopecia areata, compared with 9.2% with placebo.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
European Commission authorizes GSK's HIV prevention drugThe European Commission has granted authorization to GSK's HIV-focused division, ViiV Healthcare, for its cabotegravir in both long-acting injectable and tablet forms.
Baca lebih lajut »
Poland proposes ban on Russian diamonds, LPG in new sanctions packageThe Polish proposal will now be considered by the European Commission.
Baca lebih lajut »
Thai cabinet approves higher budget of $97.6 billion for fiscal year 2024 By ReutersThai cabinet approves higher budget of $97.6 billion for fiscal year 2024
Baca lebih lajut »
Hyundai Motor's South Korea union approves wage deal - union official By ReutersHyundai Motor's South Korea union approves wage deal - union official
Baca lebih lajut »
Anchorage Assembly approves contract for legal services in Demboski lawsuitAnchorage Assembly approves contract for legal services in Demboski lawsuit
Baca lebih lajut »
Indonesia parliament committee approves govt's $216.3 billion budget for 2024 By ReutersIndonesia parliament committee approves govt's $216.3 billion budget for 2024
Baca lebih lajut »